CClinicalTrials.gg
CompletedNCT04854720Updated May 6, 2021

Clinical Efficacy of Different Fissure Sealant Materials in the Newly Erupted Non-Carious First Permanent Molars

An interventional study of Fuji® II LC CAPSULE and Clinpro™ XT Varnish in Fissure Sealant, sponsored by Izmir Katip Celebi University. Completed at 1 site in Turkey. Open to participants aged 5 Years to 9 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-05-06.

Sponsored by Izmir Katip Celebi University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 2 years 1 month after the study started (first participant enrolled Mar 2019, registered Apr 2021).
Phase
Not applicable
Study type
Interventional
Enrollment
182
Allocation
Randomized
Ages
5 Years to 9 Years
Sex
All
01

Study summary

The aim of this study is to compare the clinical retention rates, marginal adaptation, marginal discoloration and secondary caries formation of two different types of resin-modified glass ionomers (Fuji® II LC; Clinpro™ XT Varnish) and giomer-containing fissure sealant materials (Beautifil Flow) with glass ionomer-containing fissure sealant material (Fuji Triage®) used on newly erupted non-carious first permanent molars as a fissure sealant.

The study included 384 teeth belonging to 182 children, aged between 5 to 9 years old, who have two newly erupted mandibular permanent first molars.

Read the detailed description

Firstly, patients were randomly allocated to three main groups: Group 1; Fuji II LC/Fuji Triage (Control) (62 patients), Group 2; Clinpro XT Varnish/Fuji Triage (Control) (60 patients), Group 3; Beautifil Flow/Fuji Triage (Control) (60 patients). After clinical applications, all samples were evaluated in terms of retention, marginal adaptation, marginal discoloration and secondary caries formation using modified USPHS criteria in 6th, 12th and 18th months. Also samples were evaluated in terms of remineralization effect using the laser fluorescence method. Evaluations on occlusal and buccal surfaces were performed separately.

02

Conditions studied

  • Fissure Sealant

Keywords

  • Conventional glass ionomer
  • fissure sealant
  • giomer
  • laser fluorescence
  • newly erupted teeth
  • resin modified glass ionomer
03

In context

Lead sponsor

Izmir Katip Celebi University is the lead sponsor of 191 studies on the registry; 40 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
5 Years to 9 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Children who have two newly erupted non-carious mandibular permanent first molars that fissure sealant is indicated,
  • Newly erupted first permanent molars show scores of 0 (Sound tooth surface)-1(First visual change in enamel) according to ICDAS II,
  • Newly erupted first permanent molars show scores between 0-13 by using DIAGNOdent device,
  • Children who haven't any systemic disease that prevents the application,
  • Cooperative children who allowed the clinical applications.

Exclusion criteria

Exclusion Criteria:

  • Teeth with proximal and initial caries,
  • Teeth with applied fissure sealant,
  • Teeth with developmental defects such as hypoplasia and restorations,
  • Non-cooperative children who don't allow the clinical applications,
  • Children and parents who denied the participation in the follow-up appointments.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
182 participants (actual)

Study arms

  • Experimental
    Group 1 (Fuji II LC-Fuji Triage)

    In Group 1, newly erupted mandibular permanent first molars were sealed with resin-modified glass ionomers containing fissure sealant material (Fuji® II LC, GC Corporation, Tokyo, Japan) (test 1). The other first molars were sealed with glass ionomers containing fissure sealant material (Fuji Triage®, GC Corporation, Tokyo, Japan) (control).

    Device: Fuji® II LC CAPSULE · Device: Fuji Triage® CAPSULE

  • Experimental
    Group 2 (Clinpro XT Varnish-Fuji Triage)

    In Group 2, newly erupted mandibular permanent first molars were sealed with resin-modified glass ionomers containing fissure sealant material (Clinpro™ XT Varnish, 3M ESPE, St. Pauls, Miniapolis, MN, USA) (test 2). The other first molars were sealed with glass ionomers containing fissure sealant material (Fuji Triage®, GC Corporation, Tokyo, Japan) (control).

    Device: Clinpro™ XT Varnish · Device: Fuji Triage® CAPSULE

  • Experimental
    Group 3 (Beautiful Flow- Fuji Triage)

    In Group 3, newly erupted mandibular permanent first molars were sealed with Giomer containing fissure sealant material (Beautifil Flow, Shofu, Kyoto, Japan) (test 3). The other first molars were sealed with glass ionomers containing fissure sealant material (Fuji Triage®, GC Corporation, Tokyo, Japan) (control).

    Device: Beautifil Flow · Device: Fuji Triage® CAPSULE

Interventions

  • DeviceFuji® II LC CAPSULE

    Fuji® II LC is a resin modified glass ionomer contained, fluoride releasing and light-cured material. Since the product is tolerant to moisture and saliva, it's used for fissure sealant of newly erupted teeth. Test 1 newly erupted first permanent molars were cleaned with a pumice paste using a bristle brush and isolated with cotton rolls. Then, 20% cavity conditioner was applied to all surfaces of the tooth for 10 seconds.The tooth surface was rinsed with water and dried. Thereafter, Fuji® II LC was applied to the pits and fissures on the tooth surface using a brush. Then, the varnish was applied and cured according to the manufacturer's instructions.

    Also known as: Fuji® II LC CAPSULE, GC Corporation, Tokyo, Japan

  • DeviceClinpro™ XT Varnish

    Clinpro™ XT Varnish is a resin modified glass ionomer containing, fluoride-releasing, light-cured varnish. Since the product is tolerant to moisture and saliva, it is used for fissure sealant of newly erupted teeth. The product can be recharged with fluoride using fluoride-containing products. Test 2 newly erupted first permanent molars were cleaned with a pumice paste using a bristle brush and isolated with cotton rolls. Then, 35% phosphoric acid was applied to all surfaces of the tooth for 15 seconds.Then the tooth surface was rinsed with water and dried. Thereafter, Clinpro™ XT Varnish was applied in compliance with the manufacturers' instructions.

    Also known as: Clinpro™ XT Varnish, 3M ESPE, St. Pauls, Miniapolis, MN, USA

  • DeviceBeautifil Flow

    Beautiful Flow is a Giomer contained, fluoride releasing and light cured material. The product contains pre-reacted glass ionomer particles (PRG). It is a high water resistant material. It is used for fissure sealant. Test 3 newly erupted first permanent molars were cleaned with a pumice paste using a bristle brush and isolated with cotton rolls. Then, 7% phosphoric acid was applied to all surfaces of the tooth for 10 seconds. Then the tooth surface was rinsed with water and dried. Afterwards, a two-stage self-etch adhesive system was applied. Thereafter, Beautiful Flow was applied in compliance with the manufacturers' instructions.

    Also known as: Beautifil Flow, Shofu, Kyoto, Japan

  • DeviceFuji Triage® CAPSULE

    Fuji Triage® is a new generation glass ionomer containing with low viscosity, high fluoride content and light curing materials. Since the product is tolerant of moisture and saliva, it is used for fissure sealant of newly erupted teeth. Control newly erupted first permanent molars were cleaned with a pumice paste using a bristle brush and isolated with cotton rolls. Then, 20% cavity conditioner was applied to all surfaces of the tooth for 10 seconds.Then the tooth surface was rinsed with water and dried. Thereafter,Fuji Triage® was applied to the pits and fissures on the tooth surface using a brush. Thereafter, the varnish was applied and cured according to the manufacturer's instructions.

    Also known as: Fuji Triage® CAPSULE, GC Corporation, Tokyo, Japan

06

What researchers measure

Primary outcomes

  1. The assessment of clinical retention rates of fissure sealants applied to newly erupted permanent first molars.

    The primary outcome of the study was the assessment of clinical retention rates at 18th months.

    Time frame: 18 months after the clinical applications

  2. The assessment of marginal adaptation rates of fissure sealants applied to newly erupted permanent first molars.

    The primary outcome of the study was the assessment of marginal adaptation rates at 18th months.

    Time frame: 18 months after the clinical applications

  3. The assessment of marginal discoloration rates of fissure sealants applied to newly erupted permanent first molars.

    The primary outcome of the study was the assessment of marginal discoloration rates at 18th months.

    Time frame: 18 months after the clinical applications

  4. The assessment of secondary caries rates of fissure sealants applied to newly erupted permanent first molars.

    The primary outcome of the study was the assessment of secondary caries rates at 18th months.

    Time frame: 18 months after the clinical applications

Secondary outcomes

  1. The assessment of remineralization capacity using DIAGNOdent device

    The secondary outcome of the study was the assessment of remineralization capacity using DIAGNOdent, at 18th months.

    Time frame: 18 months after the clinical applications

07

Study locations

1 site
  • Izmir Katip Celebi University
    Izmir, Turkey
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 6, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04854720
Lead sponsor
Izmir Katip Celebi University
Responsible party
Merve AKCAY (Assoc. Prof. Dr., Izmir Katip Celebi University) — Principal investigator
First posted
Apr 22, 2021
Start date
Mar 10, 2019
Primary completion
Nov 16, 2020
Completion
Jan 11, 2021
Last update
May 6, 2021

Study contacts

Merve Akcay, assoc. prof.
study chair · Izmir Katip Celebi Uni

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion